Process for producing allyl alcohol derivatives useful in prostaglandin
synthesis
    11.
    发明授权
    Process for producing allyl alcohol derivatives useful in prostaglandin synthesis 失效
    制备用于前列腺素合成的烯丙醇衍生物的方法

    公开(公告)号:US4094886A

    公开(公告)日:1978-06-13

    申请号:US767165

    申请日:1977-02-09

    摘要: A novel process for producing allyl alcohol derivatives having the formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group; and R.sup.2 represents an alkyl group which can have an inert substituent; and X represents a hydrogen atom, a hydroxy, an alkoxy, a tetrahydropyranyloxy or a silyloxy group; which are useful intermediates for the syntheses of prostaglandins and analogous compounds is disclosed. In the process, the allyl alcohol derivatives are produced starting from .beta.-keto-esters and azides through a series of reactions.

    摘要翻译: 一种制备式(XI)的烯丙醇衍生物的新方法,其中R1表示氢原子或低级烷基; 并且R 2表示可具有惰性取代基的烷基; X表示氢原子,羟基,烷氧基,四氢吡喃基氧基或甲硅烷氧基; 其是用于合成前列腺素和类似化合物的有用的中间体。 在此过程中,烯丙醇衍生物通过一系列反应从β-酮酯和叠氮化物开始制备。

    .beta.-Phenoxy or substituted phenoxy ethanol compounds
    12.
    发明授权
    .beta.-Phenoxy or substituted phenoxy ethanol compounds 失效
    {62-苯氧基或取代的苯氧基乙醇化合物

    公开(公告)号:US4016186A

    公开(公告)日:1977-04-05

    申请号:US527417

    申请日:1974-11-26

    IPC分类号: C07C69/003 C07C69/76

    CPC分类号: C07C69/003

    摘要: Novel .beta.-phenoxy- or substituted phenoxy-ethanol compounds or esters thereof expressed by the formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group, R.sup.2 is a hydrogen atom or a substituent, Y is --OH group or group ##STR2## R.sup.3 is an alkyl group, and n is an integer of 1 to 3. These compounds have juvenile hormone activities, and are useful for hormonal pest control and increased production of silkworm cocoons.

    摘要翻译: 新的β-苯氧基 - 或取代的苯氧基 - 乙醇化合物或其由下式表示的酯其中R 1是氢原子或烷基,R 2是氢原子或取代基,Y是-OH基团或基团 R3为烷基,n为1〜3的整数。

    Process for preparing bicyclic .gamma.-lactone
    13.
    发明授权
    Process for preparing bicyclic .gamma.-lactone 失效
    制备双环{65-内酯的方法

    公开(公告)号:US3970673A

    公开(公告)日:1976-07-20

    申请号:US582002

    申请日:1975-05-29

    CPC分类号: C07D307/935 C07D307/83

    摘要: A process for preparing a bicyclic .gamma.-lactone represented by the formula (I) ##SPC1##wherein R represents a hydrogen atom or a straight or branched chain alkyl group having 1 to 4 carbon atoms and n is an integer of 1 to 6, which comprises condensing a cycloalkene diol compound represented by the formula (II) ##SPC2##wherein n is as defined above, with an orthocarboxylic acid ester represented by the formula (III)r--ch.sub.2 --c(or.sup.1).sub.3 (iii)wherein R is as defined above and R.sup.1 represents a straight or branched chain alkyl group having 1 to 4 carbon atoms, in the presence of an acidic catalyst.

    摘要翻译: 一种制备由式(I)表示的双环γ-内酯的方法,其中R表示氢原子或具有1至4个碳原子的直链或支链烷基,n为1至6的整数,其包括将 与由式(III)表示的原碳酸酯的式(II)表示的式(II)表示的环烯烃二醇化合物与式(III)表示的R-CH 2 -C(OR 1)3(III)其中R如上所定义,R 1表示 在酸性催化剂存在下,具有1至4个碳原子的直链或支链烷基。

    Nerve growth factor production accelerators and compositions for
preventing or treating neuronal degeneration
    17.
    发明授权
    Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration 失效
    神经生长因子生产促进剂和预防或治疗神经元变性的组合物

    公开(公告)号:US5846977A

    公开(公告)日:1998-12-08

    申请号:US675385

    申请日:1996-07-02

    CPC分类号: A61K31/4745 A61K31/47

    摘要: Nerve growth factor production accelerating agents containing oxazopyrroloquinolines, pyrroquinolinequinones and/or their esters as active ingredient are provided. As the oxazopyrroloquinolines and their esters exhibit such production accelerating activity, they are suitably utilized for preventing and treating functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis. As the pyrroquinolinequinones and their esters exhibit strong nerve growth factor production accelerating activity, they are suitably utilized for preventing and treating functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neurosis, etc.

    摘要翻译: 提供含有恶唑吡咯并喹啉,吡咯醌啉醌和/或其酯作为活性成分的神经生长因子生产促进剂。 由于恶唑吡咯并喹啉及其酯类具有这种生产促进活性,因此适用于预防和治疗中枢神经系统功能紊乱,特别是阿尔茨海默氏痴呆,脑缺血和脊髓损伤,以及周围神经系统的功能障碍 ,外周神经系统创伤和糖尿病性神经症。 由于吡咯醌及其酯显示强烈的神经生长因子生产促进活性,因此适用于预防和治疗周围神经系统功能紊乱,特别是周围神经系统创伤,糖尿病性神经症等。

    Nerve growth factor production accelerators and compositions for
preventing or treating neuronal degeneration
    18.
    发明授权
    Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration 失效
    神经生长因子生产促进剂和预防或治疗神经元变性的组合物

    公开(公告)号:US5589481A

    公开(公告)日:1996-12-31

    申请号:US200912

    申请日:1994-02-22

    CPC分类号: A61K31/4745 A61K31/47

    摘要: Nerve growth factor production accelerating agents containing oxazopyrroloquinolines, pyrroquinolinequinones and/or their esters as active ingredient are provided. As the oxazopyrroloquinolines and their esters exhibit such production accelerating activity, they are suitably utilized for preventing and treating functional disorders of central nervous system, particularly, Alzheimer's dementia, cerebral ischemia and spinal trauma, as well as for functional disorders of Peripheral nervous system, particularly, peripheral nervous system trauma and diabetic neurosis. As the pyrroquinolineguinones and their esters exhibit strong nerve growth factor production accelerating activity, they are suitably utilized for preventing and treating functional disorders of peripheral nervous system, particularly, peripheral nervous system trauma, diabetic neuropathy, etc.

    摘要翻译: 提供含有恶唑吡咯并喹啉,吡咯醌啉醌和/或其酯作为活性成分的神经生长因子生产促进剂。 由于恶唑吡咯并喹啉及其酯表现出这种生产促进活性,因此适用于预防和治疗中枢神经系统功能障碍,特别是阿尔茨海默氏痴呆,脑缺血和脊髓创伤,以及外周神经系统的功能障碍 ,外周神经系统创伤和糖尿病性神经症。 由于吡咯喹啉酮及其酯表现出强烈的神经生长因子生产促进活性,因此适用于预防和治疗周围神经系统功能紊乱,特别是周围神经系统创伤,糖尿病性神经病变等。

    Gene coding for eicosapentaenoic acid synthesizing enzymes and process
for production of eicosapentaenoic acid
    19.
    发明授权
    Gene coding for eicosapentaenoic acid synthesizing enzymes and process for production of eicosapentaenoic acid 失效
    二十碳五烯酸合成酶的基因编码和二十碳五烯酸的生产方法

    公开(公告)号:US5798259A

    公开(公告)日:1998-08-25

    申请号:US752929

    申请日:1996-11-20

    摘要: There is provided an advantageous process for production of EPA by a gene recombinant technique wherein genes coding for biosynthesis enzymes for eicosapentaenoic acid (EPA) useful as pharmaceuticals, agrochemicals, foods, feeds or the like is obtained from microorganisms. EPA is produced by obtaining genes coding for eicosapentaenoic acid (EPA) biosynthesis enzymes, constructing a plasmid by joining the genes to a vector, transforming E. coli with the plasmid, and culturing the transformed E. coli.

    摘要翻译: 提供了通过基因重组技术生产EPA的有利方法,其中可从微生物获得编码二十碳五烯酸(EPA)的生物合成酶的基因,其用作药物,农业化学品,食品,饲料等。 EPA通过获得编码二十碳五烯酸(EPA)生物合成酶的基因产生,通过将基因连接到载体构建质粒,用质粒转化大肠杆菌,并培养转化的大肠杆菌。

    Method for treating hepatitis
    20.
    发明授权
    Method for treating hepatitis 失效
    治疗肝炎的方法

    公开(公告)号:US5436269A

    公开(公告)日:1995-07-25

    申请号:US87708

    申请日:1993-11-08

    IPC分类号: A61K31/20 A61K31/225

    CPC分类号: A61K31/20

    摘要: A drug for hepatic diseases, particularly an ameliorant for hepatic functions and a drug for hepatitis, containing docosahexaenoic acid or a derivative thereof (DHA) as an active ingredient. The DHA as the active drug ingredient, though also taking part in the metabolism of cholesterol formed in vivo and exuding into the plasma, mainly metabolizes that cholesterol specifically which is accumulated in hepatic microsomes as a result of hypometabolism or dysbolism to thereby bring about the recovery of flexibility of a microsome lipid membrane, thus enhancing the enzymatic activity, and to significantly reduce a triglyceride, thus being prospective as an ameliorant for hepatic functions in treating fatty liver, hepatic cirrhosis, etc. The invention also provides a drug for hepatitis, which can inhibit the induction of hepatitis which is one of the factor causative of chronic hepatitis, hepatocirrhosis, hepatocellular carcinoma, hepatic insufficiency, etc.

    摘要翻译: PCT No.PCT / JP92 / 01486 Sec。 371日期:1993年11月8日 102(e)日期1993年11月8日PCT提交1992年11月13日PCT公布。 公开号WO93 / 09772 日期:1993年5月27日。一种肝脏疾病药物,特别是肝功能改善剂和含有二十二碳六烯酸或其衍生物(DHA)作为活性成分的肝炎药物。 作为活性成分的DHA虽然也参与了在体内形成的胆固醇代谢并渗入血浆中,但主要代谢胆固醇特异性地代谢由于代谢异常或排尿困难导致的肝微粒体中累积的胆固醇,从而导致恢复 微粒体脂质膜的柔韧性,从而增强酶活性,并显着降低甘油三酯,因此作为治疗脂肪肝,肝硬化等肝功能的改善剂是预期的。本发明还提供了一种用于肝炎的药物,其中 可以抑制肝炎的诱导,这是导致慢性肝炎,肝硬化,肝细胞癌,肝功能不全等的因素之一。